Cart
sales@molnova.com
Theralizumab
CAS No. 906068-56-2
Theralizumab( —— )
Catalog No. M36814 CAS No. 906068-56-2
Theralizumab (TGN1412) is an anti-CD28-targeting monoclonal antibody that directly stimulates T cells.
Purity : >98% (HPLC)
COA
Datasheet
HNMR
HPLC
MSDS
Handing Instructions
| Size | Price / USD | Stock | Quantity |
| 2MG | 1132 | Get Quote |
|
| 5MG | 1881 | Get Quote |
|
| 10MG | 3164 | Get Quote |
|
| 25MG | 4572 | Get Quote |
|
| 50MG | 6146 | Get Quote |
|
| 500MG | Get Quote | Get Quote |
|
| 1G | Get Quote | Get Quote |
|
Biological Information
-
Product NameTheralizumab
-
NoteResearch use only, not for human use.
-
Brief DescriptionTheralizumab (TGN1412) is an anti-CD28-targeting monoclonal antibody that directly stimulates T cells.
-
DescriptionTheralizumab (TGN1412) is a superagonist anti-CD28 monoclonal antibody that directly stimulates T cells. Theralizumab can be used for the research of rheumatoid arthritis.
-
In Vitro——
-
In Vivo——
-
Synonyms——
-
PathwayOthers
-
TargetOther Targets
-
RecptorOthers
-
Research Area——
-
Indication——
Chemical Information
-
CAS Number906068-56-2
-
Formula Weight
-
Molecular Formula——
-
Purity>98% (HPLC)
-
Solubility——
-
SMILES——
-
Chemical Name——
Shipping & Storage Information
-
Storage(-20℃)
-
ShippingWith Ice Pack
-
Stability≥ 2 years
Reference
1. Thomas Hünig. The rise and fall of the CD28 superagonist TGN1412 and its return as TAB08: a personal account. FEBS J. 2016 Sep;283(18):3325-34.?
molnova catalog
related products
-
Benzyl-α-GalNAc
Benzyl-α-GalNAc is a potent inhibitor of O-glycosylation and is used to reduce mucin on cell surfaces.
-
Adenosine N1-oxide
Adenosine N1-oxide, which is found in royal jelly, inhibited the secretion of inflammatory mediators by activated macrophages and reduced lethality in lipopolysaccharide (LPS)-induced endotoxin shock.
-
Intermediate of Preg...
Used as organic synthesis and medicine intermediate.
